CoChat

New approaches to symptomatic treatments for Alzheimer’s disease

Open access
Cummings, Jeffrey · 2021 · Molecular Neurodegeneration

The DOI matches its Crossref record; 127 of the 128 references it cites were found in a registry or an index.

Abstract

Background: Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder. Discussion: There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD. Conclusions: Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-021-00424-9

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Number of cognitive enhancing agents for Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]
Fig. 1 Number of cognitive enhancing agents for Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]CC BY · PubMed Central
Fig. 2 Number of agents addressing neuropsychiatric symptoms of Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]
Fig. 2 Number of agents addressing neuropsychiatric symptoms of Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 127 references

Cited by

See all 247

Metadata

Authors
Cummings, J.
Affiliations
University of Nevada, Las Vegas (US)
Corresponding author
Cummings, Jeffrey
Venue
Molecular Neurodegeneration
Published
2021-01-13
Volume
16
Issue
1
Pages
2-2
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3120244708
Cited by
226
References
128
Citations by year
2026: 25 · 2025: 39 · 2024: 47 · 2023: 42 · 2022: 45 · 2021: 28
FWCI
5.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of General Medical Sciences (P20GM109025)
  • National Institute of Neurological Disorders and Stroke (U01NS093334)
  • National Institute on Aging (R01AG053798)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, symptomatic treatment, nootropic drugs, neuropsychiatric symptoms, psychotropic drugs, insomnia, psychosis, apathy, agitation, clinical trial design, outcome measures
MeSH terms
Aged, Alzheimer Disease, Anxiety, Cognition, Depression, Humans, Psychomotor Agitation, Apathy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New approaches to symptomatic treatments for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-021-00424-9
The paper
Cummings, J. (2021). New approaches to symptomatic treatments for Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00424-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.